Displaying drugs 11601 - 11625 of 11723 in total
NBI-6024
NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.
Investigational
IDM-4
IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes. Trials of this drug have most likely...
Investigational
Matched Description: … It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling …
Sifalimumab
Sifalimumab is a fully human monoclonal antibody targeting interferon-alpha. The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders, and may be associated with disease activity. Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to...
Investigational
Matched Description: … Sifalimumab is a fully human monoclonal antibody targeting interferon-alpha. …
Etilamfetamine
Etilamfetamine is also known as N-ethylamphetamine and is in the Canadian Legislation - The Controlled Drugs and Substances Act, and is a Schedule 1 controlled drug. Like other amphetamines, this amphetamine analog was used as an appetite suppressant in the 1950s. However, being on the controlled drug and substance act...
Experimental
Matched Description: … N-ethylamphetamine and is in the Canadian Legislation - The Controlled Drugs and Substances Act, and is a …
Besifovir dipivoxil
Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA. Besifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus.
Investigational
Matched Description: … Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. …
Bisegliptin
Bisegliptin is a compound for the treatment of type 2 diabetes. It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion and lowering blood glucose levels without hypoglycemic effects.
Investigational
Matched Description: … Bisegliptin is a compound for the treatment of type 2 diabetes. …
Maropitant
Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats.
Vet approved
Matched Description: … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis …
Gaboxadol
Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing effects of benzodiazepines. Development of Gaboxadol was stopped in March 2007 after concerns regarding safety and efficacy. It acts on the GABA system, but in...
Investigational
Matched Description: … It acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives …
Darapladib
Investigational
PF-07304814
PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro), which is used by viruses like SARS-CoV-2 to assemble and multiply . Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its anti-viral effects . PF-07304814, developed by Pfizer, was first identified during the...
Investigational
Matched Description: … PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro) …
Brasofensine
Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K. In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.
Investigational
MK-1454
A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities. Upon intratumoral (IT) administration, STING agonist MK-1454 binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB)...
Investigational
Matched Description: … A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), ... This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. …
GC-373
GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, GC-376 free acid[A219031,A219036]. It is an inhibitor of Mpro (otherwise known as 3CLpro), a viral encoded protease that cleaves and activates functional proteins involved in viral replication and transcription . GC-373 has been shown to inhibit the Mpro...
Experimental
Matched Description: … GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, [GC-376 free acid][A219031 ... It is an inhibitor of Mpro (otherwise known as 3CLpro), a viral encoded protease …
Iclaprim
Investigational
Vapitadine
Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis. An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.
Investigational
Matched Description: … Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions …
3,4-Methylenedioxy-N-isopropylamphetamine
MDI-P has demonstrated potent anti-HIV activity. MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF").
Investigational
Matched Description: … MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF …
Quaternium-18
Quaternium-18 is a mixture of quaternary ammonium chloride salts. Quaternium-18 Hectorite and Bentonite are the reaction products of Quaternium-18 with clays. These compounds are poorly absorbed through the skin. Acute oral and percutaneous toxicity tests in animals indicate that they exhibit little or no systemic toxic effects.
Experimental
Matched Description: … Quaternium-18 is a mixture of quaternary ammonium chloride salts. …
Lomerizine
Lomerizine is a diphenylmethylpiperazine calcium channel blocker[A245378, A245383] with relatively selective central nervous system (CNS) effects. This drug is used to prophylactically treat migraines[A245368, A245373] and is also being investigated against eye-related diseases that are associated with local circulatory disturbances, an example being normal-tension glaucoma.
Experimental
Matched Description: … Lomerizine is a diphenylmethylpiperazine calcium channel blocker[A245378, A245383] with relatively selective …
Phosphorus P-32
Phosphorus P-32 is a radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity. Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular biological macromolecules, resulting in tumor cell death.
Experimental
Matched Description: … Phosphorus P-32 is a radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity …
MBO7133
MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer. AraC's anti-cancer activity is associated with its ability to be converted to its biologically active form, araCTP. However, araC is only slowly...
Investigational
Matched Description: … MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is ... MB07133 uses our HepDirect technology to target a prodrug form of araCMP specifically to the liver. …
Betameprodine
Betameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances. The stereoisomer alphameprodine is similarly classified, and was more widely used (both are referred to as Meprodine). Betameprodine is a structural analogue of meperidine. It exerts physiological effects characteristic of opioids,...
Experimental
Illicit
Matched Description: … Betameprodine is a structural analogue of meperidine. …
Urelumab
Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in...
Investigational
Matched Description: … Urelumab is a fully human antibody that targets CD137. …
LV-SMENP Vaccine
LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which are based on domains of selected viral proteins. This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs).
As of August 2020, this vaccine...
Investigational
Matched Description: … LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises …
PN0621
PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.
Investigational
CIGB-258 peptide
CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular variant. As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens...
Investigational
Matched Description: … CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular …
Displaying drugs 11601 - 11625 of 11723 in total